Affordable Access

Exquisite Sensitivity of TP53 Mutant and Basal Breast Cancers to a Dose-Dense Epirubicin−Cyclophosphamide Regimen

Authors
Publisher
Public Library of Science
Publication Date
Source
PMC
Keywords
  • Research Article
Disciplines
  • Biology
  • Medicine

Abstract

Hugues de The and colleagues report thatTP53 status is a predictive factor for responsiveness in breast cancers to a dose-dense epirubicin-cyclophosphamide chemotherapy regimen, and suggests that this regimen might be well suited for patientsTP53 mutant tumors.

There are no comments yet on this publication. Be the first to share your thoughts.